Indigotindisulfonate sodium
Bludigo (indigotindisulfonate sodium) is a small molecule pharmaceutical. Indigotindisulfonate sodium was first approved as Bludigo on 2022-07-08.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Bludigo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indigotindisulfonate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BLUDIGO | Provepharm | N-216264 RX | 2022-07-08 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bludigo | New Drug Application | 2023-01-20 |
| indigo carmine | unapproved drug other | 2021-04-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
INDIGOTINDISULFONATE SODIUM, BLUDIGO, PROVEPHARM SAS | |||
| 2027-07-08 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
117 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | — | 1 | 1 | 1 | 10 | 13 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | 1 | 7 | 8 |
| Leukemia | D007938 | — | C95 | 1 | 1 | 3 | 1 | 1 | 7 |
| Neoplasms | D009369 | — | C80 | — | — | — | 1 | 6 | 7 |
| Promyelocytic leukemia acute | D015473 | — | C92.4 | — | 1 | 2 | 1 | 1 | 5 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | 1 | 2 | 3 |
| Ureteral obstruction | D014517 | — | — | — | — | — | 1 | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | — | — | 1 | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | — | — | — | 1 | — | 1 |
| Duodenal neoplasms | D004379 | — | — | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenoma | D000236 | — | — | — | — | 1 | — | 7 | 8 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 6 | 2 | — | 1 | 7 |
| Colonic neoplasms | D003110 | — | C18 | — | — | 1 | — | 2 | 3 |
| Endoscopic mucosal resection | D000069916 | — | — | — | — | 1 | — | 2 | 3 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | — | 2 | — | — | 2 |
| Urinary incontinence | D014549 | — | R32 | — | — | 2 | — | — | 2 |
| Enuresis | D004775 | — | R32 | — | — | 2 | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | 1 | — | — | 2 |
| Recurrence | D012008 | — | — | — | — | 1 | — | 1 | 2 |
| Diarrhea | D003967 | — | R19.7 | — | — | 1 | — | 1 | 2 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hereditary nonpolyposis colorectal neoplasms | D003123 | EFO_0007354 | — | — | 1 | — | — | 4 | 5 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | — | — | — | 2 |
| Eczema | D004485 | — | L30.9 | — | 2 | — | — | — | 2 |
| Dermatitis | D003872 | — | L30.9 | — | 2 | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | — | — | — | 1 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | — | 1 | — | — | — | 1 |
| Rhabdomyosarcoma | D012208 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colonic polyps | D003111 | — | K63.5 | 1 | — | — | — | 6 | 7 |
| Embolism | D004617 | — | — | 1 | — | — | — | 5 | 6 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 1 | — | — | — | 4 | 5 |
| Hiv | D006678 | — | O98.7 | 1 | — | — | — | — | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | — | 7 | 7 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | — | — | — | 7 | 7 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 6 | 6 |
| Polyps | D011127 | EFO_0000662 | — | — | — | — | — | 5 | 5 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | — | 5 | 5 |
| Ulcer | D014456 | MPATH_579 | — | — | — | — | — | 5 | 5 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 4 | 4 |
| Syndrome | D013577 | — | — | — | — | — | — | 4 | 4 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 3 | 3 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | — | — | — | — | 3 | 3 |
Show 62 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Indigotindisulfonate sodium |
| INN | — |
| Description | Indigo carmine, or 5,5′-indigodisulfonic acid sodium salt, is an organic salt derived from indigo by aromatic sulfonation, which renders the compound soluble in water. It is approved for use as a food colorant in the U.S and E.U. to produce a blue color. It has the E number E132. It is also a pH indicator.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1/C(=C2\Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21.[Na+].[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 860-22-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105023 |
| ChEBI ID | 31695 |
| PubChem CID | 5284351 |
| DrugBank | DB11577 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,918 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
35 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use